Sarepta Therapeutics, Inc.
SRPT
$20.22
$0.160.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 611.09M | 744.86M | 658.41M | 467.17M | 362.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 611.09M | 744.86M | 658.41M | 467.17M | 362.93M |
| Cost of Revenue | 356.95M | 911.01M | 332.26M | 316.17M | 224.24M |
| Gross Profit | 254.14M | -166.16M | 326.16M | 151.00M | 138.70M |
| SG&A Expenses | 137.90M | 133.63M | 163.87M | 128.20M | 138.80M |
| Depreciation & Amortization | 667.00K | 601.00K | 601.00K | 602.00K | 601.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 495.51M | 1.05B | 496.73M | 444.98M | 363.63M |
| Operating Income | 115.58M | -300.39M | 161.68M | 22.20M | -701.00K |
| Income Before Tax | 153.64M | -383.52M | 171.74M | 34.01M | 13.58M |
| Income Tax Expenses | -43.25M | 63.99M | 12.69M | 395.00K | 7.12M |
| Earnings from Continuing Operations | 196.89M | -447.51M | 159.05M | 33.61M | 6.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 196.89M | -447.51M | 159.05M | 33.61M | 6.46M |
| EBIT | 115.58M | -300.39M | 161.68M | 22.20M | -701.00K |
| EBITDA | 126.42M | -290.41M | 172.14M | 32.00M | 8.02M |
| EPS Basic | 2.01 | -4.60 | 1.65 | 0.35 | 0.07 |
| Normalized Basic EPS | 0.73 | -1.89 | 1.07 | 0.14 | 0.02 |
| EPS Diluted | 1.89 | -4.60 | 1.61 | 0.34 | 0.07 |
| Normalized Diluted EPS | 0.67 | -1.89 | 0.95 | 0.14 | 0.02 |
| Average Basic Shares Outstanding | 98.01M | 97.36M | 96.28M | 95.39M | 94.62M |
| Average Diluted Shares Outstanding | 106.62M | 97.36M | 108.47M | 100.45M | 99.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |